Yuyu Pharma "Collaboration with Leading US Pharmacology Experts for Multiple Sclerosis Drug Development"

Dr. Robert Persipisi (from the left), Professor Eunju Persipisi, and Yuwonsang, CEO of Yuyu Pharmaceutical, who joined Yuyu Pharmaceutical's new drug development.
[Photo by Yuyu Pharmaceutical]

[Asia Economy Reporter Lee Gwanju] Yuyu Pharma announced on the 7th that top scholars in the field of pharmacy are collaborating on the research of new drugs for multiple sclerosis and dry eye syndrome, which are currently under research and development (R&D) in the United States.

The experts cooperating in Yuyu Pharma's new drug development are Dr. Robert Pacifici from the UCLA Office of Technology Development and Professor Eunjoo Pacifici from USC University, a married couple. They provide scientific advice on new drug development and consultation on drug approval and registration.

Yuyu Pharma is currently conducting research on treatments for multiple sclerosis and dry eye syndrome in the United States. The multiple sclerosis treatment, developed through open innovation with UCLA, has identified a drug candidate that showed potential for treating multiple sclerosis in laboratory tests. It is planned to be developed as a treatment for relapsing-remitting and primary progressive multiple sclerosis in the future.

Additionally, the Phase 2 clinical trial of the dry eye syndrome treatment 'YP-P10' is progressing smoothly, targeting 240 dry eye syndrome patients at seven hospitals in the United States.

Dr. Robert Pacifici stated, "There is an unmet need for existing multiple sclerosis treatments in medical practice," adding, "The new multiple sclerosis drug that Yuyu Pharma and UCLA aim to develop is closer to a fundamental treatment beyond symptom relief."